DALLAS--(BUSINESS WIRE)--Secretome Therapeutics, a preclinical company developing novel therapies derived from neonatal mesenchymal stem cells, today announced the appointment of Angela Shen, M.D., M.B.A, to its Board of Directors.
Dr. Shen is currently the Vice President, Strategic Innovation Leaders at Mass General Brigham and has served as Chief Medical Officer (CMO) at multiple venture-backed biotech startups including Walking Fish, Arcellx, NKarta, Arvinas, and as acting CMO of Tizona. Dr. Shen has led oncology programs in a variety of pharmaceutical settings for over 17 years through all stages of drug development including IND filings, first-in-human trials, registrational trials, and NDA/BLA filings. While working in oncology clinical development at Novartis, Dr. Shen was extensively involved with in-licensing University of Pennsylvania’s CAR-T technology. She led the clinical team responsible for designing and launching the industry’s first multi-site, registration CAR-T trial, which resulted in the approval of Kymriah® (CTL019, CART-19). Previously, Dr. Shen made significant contributions to the development of several oncology drugs within Novartis, Exelixis, and Johnson & Johnson that were subsequently approved. She received a BS through Rensselaer’s accelerated biomedical program and holds an MD from Albany Medical College in New York and MBA from NYU Stern School of Business.
“I’m excited to have the opportunity to work with the Secretome team,” said Dr. Shen. “This is a highly capable team that has the conviction, expertise, and experience needed to bring potentially transformative new therapies to patients.”
“Dr. Shen is a world-class leader in the development of groundbreaking therapies for patients with cancer, and her expertise and leadership will bring significant value to Secretome,” said Vinny Jindal, Secretome Therapeutics’ President and Chief Executive Officer. “Secretome will benefit greatly from her clinical development and regulatory experience shepherding innovative, cell-based therapies to patients with unmet medical needs. We are thrilled to have her on the Secretome team.”
About Secretome Therapeutics
Secretome Therapeutics is developing first-in-class therapeutics derived from neonatal mesenchymal stem cells (nMSC) for the treatment and prevention of underserved diseases. Our lead product, STM-01, is a novel secretome in development for the prevention of cisplatin-mediated acute kidney injury.
